Citations

Clear

571 citation(s) found for "Silva, G".

Predicting Prognosis in Primary Sclerosing Cholangitis: Conventional to Functional MRI
Thompson, Cole P. , Aswani, Yashant , Carey, Elizabeth J. , Silva, Aubrienne N, Panda, Anshuman J, Venkatesh, Sudhakar K , Silva, Alvin C , Sandrasegaran, Kumar

Mayo Clinic

RadioGraphics | October 29, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1148/rg.260030 | PMID 42955837 Get It

MRI and MR cholangiopancreatography are central to the diagnosis, surveillance, and assessment of primary sclerosing cholangitis, while functional techniques such as MR elastography and gadoxetate-enhanced MRI provide complementary evolving biomarkers with potential prognostic value and utility for risk stratification.
Cholera toxin remodels intestinal immunity and suppresses systemic metabolism
Roginski, Ana Cristina , Godazgar, Mahdieh , Salgado, Caio Loureiro , Lahiri, Gourab , Woodrow, Cheyanne , Costa Lima, Bruna Genisa , Rodriguez-Castano, Gina Paola , Voth-Gaeddert, Lee , Silva, Henrique Borges da , Dietrich, Marcelo O. , Mana, Miyeko D , Florsheim, Esther Borges , Roginski, Ana C , Salgado, Caio L , Hartley McDermott, Thomas , Borges da Silva, Henrique , Florsheim, Esther

Mayo Clinic

No container title available | October 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.29.755509 | PMID 42926400 Get It

Cholera toxin (CTx) is a potent enterotoxin and widely used mucosal adjuvant, yet the acute host response to CTx itself, in the absence of a co-administered antigen, remains vague. In this study, we integrated physiological and metabolic phenotyping with intestinal transcriptomics, epithelial imaging, immune profiling, hepatic gene-expression analysis, and paired microbiome profiling to characterize the response to a single oral CTx exposure in mice. Within 24 h, CTx remodeled immune-cell composition in both epithelial and lamina propria compartments, with responses shaped by sex and genetic background. Recurrent changes included increased epithelial group 3 innate lymphoid cells, reduced lamina propria RORγt+ regulatory T cells, and decreased epithelial ILC1/NK cells in males of both strains. CTx also increased villus DCLK1+ tuft cells and reduced MUC2 immunoreactivity. Jejunal transcriptomics revealed induction of inflammatory defense, glycolytic, autophagy, and lipid-utilization programs together with suppression of proliferative and mitochondrial programs, consistent with coordinated stress adaptation. These local changes were accompanied by rapid restructuring of the fecal microbial community and by systemic hypometabolism, despite markedly different hypothermic responses across strains. CTx also elicited a selective hepatic stress and metabolic program, including conserved suppression of Cyp7a1 across sexes and strains. Together, these findings show that CTx alone rapidly reorganizes the intestinal immune, epithelial, metabolic, and microbial environment while suppressing whole-body metabolism. This work provides an integrated framework for understanding the acute host response to CTx and for interpreting its widespread use as a mucosal adjuvant.
Impact of obesity on surgical and patient-reported outcomes after masculinizing chest surgery: a systematic review and meta-analysis
Machado, Guilherme Franceschini , Matos de Albuquerque, Karine, Barros Magalhães, Caio Augusto, Gomes, Ana Carolina dos Santos, Queiroz Ferreira, Maria Fernanda , de Carvalho Lacerda, Henrique, Carvalho Silva, Arthur , Kreutz-Rodrigues, Lucas, Liang, Fan, Martinez‐Jorge, Jorys, Albuquerque, Karine Matos de , Lacerda, Henrique de Carvalho, Kreutz‐Rodrigues, Lucas , Liang, Fan

Mayo Clinic

International Journal of Transgender Health | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-18

10.1080/26895269.2026.2732195 Get It

Treatment effect discrepancy between PFS and OS in antibody-drug conjugate trials for metastatic breast cancer: a meta-epidemiologic analysis
Costa de Almeida, Luiz Felipe, Cappellaro, Anelise Poluboiarinov , Costa Rodrigues, Lorrany Larisse , Ernst, Brenda, de Melo, Andreia Cristina, Lopes da Silva, Jessé, Trapani, Dario, Ernst, Brenda , Ernst, Brenda , Almeida, Luiz F. Costa de , Noronha, Mariana Macambira , Conceição, Lucas Diniz da , Leite, Luís Felipe , Garza-Morales, Rodolfo , Melo, Andréia Cristina de , Tarantino, Paolo , Batalini, Felipe

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag324 | PMID 42720590 Get It

Abstract Objective The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate threshold effect (STE). Methods PubMed, Embase, Cochrane, and ClinicalTrials.gov were searched for published randomized controlled phase II–IV trials evaluating ADCs in mBC and reporting hazard ratios (HRs) for both PFS and OS. A meta-epidemiological approach was used. The primary metric was the ratio of hazard ratios (rHR = HR_PFS/ HR_OS), with rHR < 1 indicating a larger effect on PFS. Trial-level associations were assessed using weighted linear regression (R²) and Spearman’s correlation. Results Twenty-one trials (n = 21; 18 phase III) evaluating nine ADCs were included. The pooled rHR was 0.79 (95% CI, 0.73–0.86), indicating a larger relative effect on PFS than OS. Numerically, the largest discrepancies were observed in triple-negative disease (rHR 0.72) and trials allowing crossover (rHR 0.71). Concordant statistical significance between endpoints occurred in 76% of the trials, whereas 24% showed a significant PFS benefit without OS improvement. The trial-level association between PFS and OS was moderate (R² = 0.62; ρ = 0.67). Conclusion Treatment effects on PFS consistently exceeded those on OS, although effect directions were highly concordant between endpoints. These findings provide an exploratory framework to contextualize the relationship between PFS and OS in ADC trials, requiring further validation in diverse clinical settings.
OA07.2. Baseline Mucosal Impedance on High-Resolution Impedance Manometry Distinguishes Active From Inactive Eosinophilic Esophagitis
Martinez, Josealberto Arenas, Freeman, Catherine, Crowell, Michael, Vela, Marcelo, Wright, Benjamin, Horsley-Silva, Jennifer, Wang, Fangfang, Arenas-Martínez, Josealberto S., Freeman, Catherine , Crowell, Michael D. , Vela, Marcelo F. , Horsley‐Silva, Jennifer L.

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.050 Get It

Abstract Topic Benign Disease: Eosinophilic Esophagitis Background Active inflammation in eosinophilic esophagitis (EoE) disrupts the mucosal barrier, leading to dilated intercellular spaces and decreased transepithelial electrical resistance. Mucosal impedance (MI) has been used to assess mucosal integrity in EoE. We evaluated whether baseline MI measured by high-resolution impedance manometry (HRIM) distinguishes active and inactive EoE. Methods We retrospectively reviewed data from patients with EoE who underwent endoscopic esophageal biopsies within three months of HRIM from 2018-2026 at our tertiary referral center and had no treatment changes between studies. We excluded patients with a history of foregut surgery, erosive esophagitis, or Barrett’s esophagus. Demographics, endoscopy and pathology results were collected by chart review. Active EoE was histologically defined as ≥15 eosinophils per high-power field. Esophageal baseline MI was measured in the 30-second landmark period for the whole esophagus (from 2 cm above LES to 2 cm below UES), distal esophagus (from 2–7 cm above LES), and mid/proximal esophagus (from 10 cm above LES to 2 cm below UES). Mann–Whitney U or T tests were used for comparisons . Optimal MI thresholds were identified by Youden index with 10,000 bootstrap validations, and interrater reliability was assessed using two-way mixed effects intraclass correlation coefficients. Results Seventy-three patients were included: 37 (51%) female, median age 52 years, median BMI 27.2 kg/m2. Fifty-seven patients (78%) had atopic history, including seasonal allergies (38, 52%), asthma (31, 42%), eczema (21, 29%), and food allergies (19, 26%). Thirty-nine patients (53%) were receiving proton pump inhibitors, 25 (34%) were not on EoE therapy, 5 (6.8%) were on swallowed topical steroids, 3 (4.1%) were on dupilumab, and 1 (1.4%) was on an elimination diet. Esophageal strictures were present in 23 patients (32%), and 45 (62%) had active EoE. Baseline MI measurement showed high interrater reliability (n=50, 2 raters; intraclass correlation coefficient 0.937–0.963, p<0.001). Basal mean and minimal impedance were significantly lower in active EoE across all segments, greatest in the distal esophagus (all p<0.05; Figure 1). ROC analysis showed high discrimination of distal mean MI, with a cutoff ≤1.91 kΩ (AUC=0.837, sensitivity 67.9%, specificity 86.7%, Youden 0.545; Figure 2). Conclusion Baseline mucosal impedance during HRIM distinguishes active from inactive EoE, with strongest discrimination in the distal esophagus, supporting MI as a potential, minimally-invasive physiologic marker of mucosal inflammation and disease activity. Clinically, MI may serve as an adjunct tool in dysphagia evaluation, prompting EoE-directed biopsy when abnormal, aiding management in biopsy–symptom discordance, and potentially supporting disease monitoring in selected patients. Larger prospective studies are warranted.
OA07.1. Clinical Features and Treatment Outcomes in Esophageal Lichen Planus: A Retrospective Multicenter Cohort Study
Wilder, Evan, Mann, Russaal, Keswani, Shiwani, Martinez, Josealberto Arenas, Codipilly, Chamil, Eluri, Swathi , Vela, Marcelo, Ramirez, Francisco, Horsley-Silva, Jennifer, Iyer, P. K. R., Arenas-Martínez, Josealberto S., Codipilly, Don C. , Vela, Marcelo F. , Kahn, Allon , Horsley‐Silva, Jennifer L. , Iyer, Prasad

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.049 Get It

Abstract Topic Benign Disease: Other Background Lichen planus is a chronic immune-mediated skin disease that may involve the esophagus. Esophageal lichen planus (ELP) is considered rare, but likely underdiagnosed. Lack of published guidelines for ELP results in significant treatment variability. Given heterogeneous practice patterns and emerging treatments, further outcome data are needed. Methods A retrospective cohort of ELP patients was assembled from 3 academic centers. Patients ≥ 18 years old were identified by ICD10 code search (L43.8) in the electronic health record, from 2006 to 2025. Patients were included if they had initial endoscopy, histology, and follow-up endoscopy showing features of LP, and excluded if there was diagnostic uncertainty, unavailable procedural documentation, or other esophageal diseases. Endoscopic findings were assessed qualitatively by manual review of reports. Data abstracted included demographics, presenting symptoms, endoscopic/histologic findings, treatment, and clinical outcomes. Statistical analysis was performed in R. Results 193 patients met inclusion criteria. Mean age at index endoscopy was 65 years, 86% were female, 98% were non-Hispanic Caucasian, 39% were ever smokers, and mean BMI was 26. Dysphagia was the most common presenting symptom (90%). Strictures were common (73%), 58% underwent dilation during initial endoscopy. Endoscopic findings included presence of sloughing (20%), exudate (22%) and friability (23%). Histology showed lymphocytic infiltrate (47%), parakeratosis/dyskeratosis (42%) and Civatte bodies (17%). Topical steroids (71%) and PPIs (63%) were used most frequently for treatment. Immunosuppressives (tacrolimus, systemic steroids, mycophenolate, methotrexate, hydroxychloroquine, cyclosporine, azathioprine, JAK inhibitor) were used in 54% of patients. Endoscopic improvement was seen in 66%, with highest response rates in tacrolimus (100%), hydroxychloroquine (100%), and a JAK inhibitor (100%). Symptom improvement was seen in 63%, with the greatest benefit seen in patients treated with a JAK inhibitor (100%) and hydroxychloroquine (86%). Conclusion In this large, multisite cohort, ELP demonstrated significant morbidity, with high rates of dysphagia, strictures, and inflammatory changes. Dilation appeared to be safe, with only a single iatrogenic perforation identified. Esophageal squamous cell cancer risk was low but present, at 4%. Despite heterogeneous treatment practices, several therapies – tacrolimus, hydroxychloroquine, and JAK inhibitors – were associated with marked endoscopic and symptomatic improvement. Prospective studies are needed to clarify the optimal approach to pharmacological management of ELP.
Key Spine Measurements: A Radiographic Guide
Arruda, Pedro H. C. , Moreira, Paulo Eduardo Borher , Morimoto, Letícia R. , Cruz, Isabela Azevedo Nicodemos da , Guimarães, Júlio B. , Rhodes, Nicholas G. , Silva, Flávio Duarte , Nico, Marcelo Astolfi Caetano , Filho, Alípio Gomes Ormond , Coelho de Arruda, Pedro H , Borher Moreira, Paulo E , Morimoto, Letícia R. , Cruz, Isabela A. N. da , Duarte Silva, Flávio , Nico, Marcelo A. C. , Ormond Filho, Alípio G

Mayo Clinic

RadioGraphics | August 20, 2026 | Volume: 46 | Issue: 9 | Pages: No page available

10.1148/rg.260023 | PMID 42623265 Get It

This slideshow presentation provides a practical image-based road map to essential spinal and pelvic radiographic measurements, with stepwise instructions and reference values, for assessment and management of spinal disorders.
Clinical Outcomes of HIF-2α inhibition in Von Hippel–Lindau Disease: A Multicenter Real-World Study
Abbas, Mousab Al, Zarka, Jabra, Silva, Alvin C. , Cingolani, Filippo , Sarfraz, Muhammed Uzair, Khan, Muhammad Ali, Tan, Winston, Costello, Brian A. , Abdul‐Muhsin, Haidar, Jang, Albert , Al Abbas, Mousab , Jang, Albert , Riaz, Irbaz B , Zarka, Jabra , Sarfraz, Muhammad Uzair, Nahhat, Fouad , Tan, Winston, Riaz, Irbaz Bin , Zakharia, Yousef

Mayo Clinic

The Oncologist | August 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag331 | PMID 42610708 Get It

Abstract Background and Objective Management of von Hippel–Lindau (VHL) disease is challenging due to multisystem involvement and limited systemic treatment options. Belzutifan has shown promising efficacy in clinical trials; however, real-world data remain limited. We aimed to evaluate its effectiveness and safety in a real-world cohort. Methods We conducted a retrospective study of 59 patients with VHL disease treated with belzutifan between August 2021 and January 2026. Objective response rates (ORR) for renal cell carcinoma (RCC), central nervous system hemangioblastomas (CNS HB), and pancreatic neuroendocrine tumors (pNET) were assessed by an independent radiologist. Retinal hemangioblastoma outcomes were evaluated through ophthalmology records by chart review. Results Median follow-up was 29 months. ORR was 27.6%, 39.6%, and 85.7% for RCC, CNS HB, and pNET, respectively. Among 13 patients with retinal hemangioblastomas (20 eyes), 17 eyes (85%) showed improvement. At data cutoff, 47 patients (79.6%) remained on treatment, while 12 (20.3%) discontinued (7 due to adverse events, 3 to disease progression, and 2 to other reasons). The most common adverse event was anemia (86.4%). Grade ≥3 events occurred in 10 patients (16.9%). The procedure rate per patient-year decreased from 0.35 in the 3 years prior to treatment to 0.08 during follow-up (Incidence Rate Ratio, 0.23; 95% CI, 0.12–0.47; P < 0.001) Conclusions Belzutifan demonstrated efficacy across VHL-associated lesions, with favorable safety profile. Most adverse events were grade 1–2. A reduction in procedure rate was observed after treatment initiation.
Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures
Wekking, Demi , Choe, Joanna Joeun, Kidd, M. , Pearce, Josie , Zelga, Piotr, Jenkins, Russell, Wang, Kenneth K., Maytin, Edward V., Hasan, Tayyaba, Silva, Pushpamali De , Choe, Joanna Joeun , Castellanos, Dario Missael Rocha , Zelga, Piotr J. , Jenkins, Russell William , Chandrasekhara, Vinay , Maytin, Edward V. , Liss, Andrew S , Hasan, Tayyaba

Mayo Clinic

Frontiers in Immunology | August 11, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1805948 | PMID 42643393 Get It

Photodynamic priming (PDP), a fallout of photodynamic therapy, transiently modulates the tumor microenvironment (TME), enhances therapeutic susceptibility, and promotes immunogenic cell death through the release of damage-associated molecular patterns (DAMPs). Pancreatic ductal adenocarcinoma (PDAC) remains non-responsive to current therapies with a desmoplastic and immunosuppressive TME that limits drug delivery and blunts responses to immune checkpoint blockade. We investigated whether PDP could enhance anti-PD1 therapy responses in PDAC using patient-derived organoids (PDOs). PDOs were treated with Visudyne and red light (25, 75, and 100 J/cm²), followed by assessment of cytotoxicity, DAMP expression (HSP60, calreticulin, HMGB1), and transcriptomic changes. Monocyte-derived dendritic cells (mDCs) from healthy donors were cocultured with PDP-treated (25 J/cm 2 ) PDOs, then with matched naïve T cells. mDC and T cell activation markers were analyzed. Pembrolizumab (anti-PD1) was added to PDO-mDC-T cell cocultures to evaluate combined effects on PDO viability and T cell activation. PDP induced dose-dependent cytotoxicity and upregulated DAMPs. Gene profiling in PDOs showed increased IFN-γ , TNF-α , and CXCL12 , with reduced PD-L1 , TGF-β1 , and FOXP1 expression. mDCs exposed to PDP-treated PDOs upregulated CD40, CD86, and MHC-II, driving activation of CD4 + and CD8 + T cells, evidenced by elevated PD1 expression. Addition of pembrolizumab further decreased PDO viability and amplified effector cytokines ( IFN-γ , TNF-α , FASLG , granzyme B, IL-2 , IL-21 ). PDP was associated with modulation of the PDAC TME toward a more immunogenic phenotype by enhancing tumor immunogenicity, activating dendritic cells and T cells, and potentiating PD1 blockade. These findings provide mechanistic support for further preclinical and clinical evaluation of PDP combined with checkpoint inhibition in PDAC.
Quantitative viscoelastic assessment of copolymer-in-oil tissue-mimicking phantoms using plane-wave and ARFI-induced shear wave elastography
Prado, Mariah Eugênia Cosso da Silva , Collazos-Burbano, David A. , Uliana, Joao Henrique, Brum, Javier , Carneiro, Antônio Adilton Oliveira , Pavan, Theo Z. , Prado, M E C S , Collazos-Burbano, D A , Uliana, J H , Brum, J , Urban, Matthew W , Carneiro, A A O , Pavan, T Z , Urban, Matthew W.

Mayo Clinic

Physics in Medicine & Biology | August 4, 2026 | Volume: 71 | Issue: 16 | Pages: 165015

10.1088/1361-6560/ae94da | PMID 42551492 Get It

Abstract Tissue-mimicking phantoms play a crucial role in evaluating new imaging modalities, simulating clinical scenarios, and ensuring the quality and reliability of imaging systems. Styrene–ethylene/butylene–styrene (SEBS) is an extremely stable and versatile material that has been recently used in ultrasound, elastography, and photoacoustic imaging across diverse applications. Despite its extensive use, a systematic viscoelastic characterization of different SEBS-based formulations reported in the literature, particularly using shear wave elastography (SWE), remains limited. To address this gap, this study investigates the viscoelastic properties of tissue-mimicking phantoms composed of SEBS, glycerol dispersions in SEBS gels, and mixtures of SEBS with low-density polyethylene (LDPE) in mineral oil, using gelatin phantoms as a reference for comparison. Viscoelastic parameters were estimated from shear wave velocity and attenuation dispersion curves using a Kelvin–Voigt model, based on SWE measurements with acoustic radiation force (ARF) excitation, shear plane-wave excitation, and complementary mechanical testing. SEBS-based phantoms exhibited broad, composition-dependent viscoelastic tunability. Increasing SEBS or LDPE content led to stiffer and more viscous responses, while glycerol primarily modulated viscosity and, at higher concentrations, also affected stiffness. Consistent and concordant values were obtained using both ARF and plane wave SWE techniques. The resulting stiffness (2–22 kPa) and viscosity (0.01–1.24 Pa⋅s) overlaps with the mechanical properties of several biological soft tissues, supporting use of these phantoms for SWE validation.